covac-1
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2021 (NCT04954469)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Spike glycoproteinImmunity, active
Spike glycoprotein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05693272 | Phase 1 | Jan 31, 2023 | Government of Canada, Government of Saskatchewan, University of Saskatchewan |
| NCT05155982 | Phase 1 | Jan 31, 2022 | Government of Canada, Government of Saskatchewan, University of Saskatchewan |
| NCT04954469 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | University of Tuebingen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Canada | Government | 2 | 0 | 1 | 2022 |
| Government of Saskatchewan | Government | 2 | 0 | 1 | 2022 |
| University of Saskatchewan | Academic/Hospital | 2 | 2 | 1 | 2022 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1